Annals of Surgical Oncology Sign the Guestbook
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gallardo-Rincon, D.
Right arrow Articles by Calderillo-Ruiz, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gallardo-Rincon, D.
Right arrow Articles by Calderillo-Ruiz, G.
Related Collections
Right arrow Surgery
Right arrow Radiation Therapy

Annals of Surgical Oncology, Vol 7, Issue 1 45-50, Copyright © 2000 by Society of Surgical Oncology

ARTICLES

Neoadjuvant chemotherapy with P-ELF (cisplatin, etoposide, leucovorin, 5-fluorouracil) followed by radical resection in patients with initially unresectable gastric adenocarcinoma: a phase II study

D. Gallardo-Rincon, L. F. Onate-Ocana and G. Calderillo-Ruiz
Medical Oncology Department, Instituto Nacional de Cancerologia, Tlalpan, Mexico DF, Mexico.

BACKGROUND: Gastric cancer is the most frequent gastrointestinal cancer in Mexico. Only 33% of cases are resectable. Our aim was to determine the activity and toxicity of the cisplatin, etoposide, leucovorin, and 5-fluorouracil combination in initially unresectable tumors and to determine its ability to permit resection. METHODS: Sixty patients with unresectable gastric adenocarcinoma were treated with cisplatin 80 mg/m2, etoposide 80 mg/m2, leucovorin 25 mg/m2, and 5-fluorouracil 800 mg/m2 by central intravenous catheter for 4 consecutive days. Two courses of this combination were followed by surgical resection. RESULTS: The overall response rate was 36.8% (20 partial responses and one complete response). By using logistic regression analysis, the tumor, node, and metastasis stage (risk ratio, 2.04; 95% confidence interval, 1.03-4.02; P = .039) was identified as the response determinant to chemotherapy. Major toxicity was grade 3 or 4 neutropenia in 67% of patients. Ten resections were performed (17.5%); five were curative and five palliative. Operative morbidity and mortality rates were 40% and 10%, respectively. The median length of survival was 7.46 and 13.3 months for nonresponders and responders, respectively (P = .011). CONCLUSIONS: The cisplatin, etoposide, leucovorin, and 5-fluorouracil combination is active in advanced gastric cancer and the toxicity level is acceptable. This treatment permits a 17.5% resection rate in previously unresectable tumors. A randomized trial of surgery vs. neoadjuvant chemotherapy plus surgery is warranted.


This article has been cited by other articles:


Home page
 Ann. Surg. Oncol.Home page
L. F. Onate-Ocana, D. Gallardo-Rincon, V. Aiello-Crocifoglio, R. Mondragon-Sanchez, and J. de-la-Garza-Salazar
The Role of Pretherapeutic Laparoscopy in the Selection of Treatment for Patients With Gastric Carcinoma: A Proposal for a Laparoscopic Staging System
Ann. Surg. Oncol., September 1, 2001; 8(8): 624 - 631.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Grundei, H. Vogelsang, K. Ott, J. Mueller, M. Scholz, K. Becker, U. Fink, J. R. Siewert, H. Höfler, and G. Keller
Loss of Heterozygosity and Microsatellite Instability as Predictive Markers for Neoadjuvant Treatment in Gastric Carcinoma
Clin. Cancer Res., December 1, 2000; 6(12): 4782 - 4788.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by the Society of Surgical Oncology.